Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial

Growth differentiation factor‐15 (GDF‐15) is associated with adverse prognosis in cardiovascular (CV) and non‐CV diseases. We evaluated the association of GDF‐15 with CV and non‐CV outcomes in the PARADIGM‐HF trial.

[1]  L. Wallentin,et al.  Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. , 2017, Clinical chemistry.

[2]  M. Pencina,et al.  Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. , 2012, European heart journal.

[3]  R. Goldschmeding,et al.  Circulating growth differentiation factor‐15 correlates with myocardial fibrosis in patients with non‐ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support , 2012, European journal of heart failure.

[4]  L. Lind,et al.  Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. , 2013, Clinical chemistry.

[5]  R. Prager,et al.  GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes. , 2016, Clinical chemistry.

[6]  G. Brabant,et al.  Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.

[7]  F. Tacke,et al.  Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsis , 2017, Disease markers.

[8]  J. Cohn,et al.  Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial , 2010, Circulation.

[9]  Andrew D. Johnson,et al.  Clinical and genetic correlates of growth differentiation factor 15 in the community. , 2012, Clinical chemistry.

[10]  B. Kestenbaum,et al.  Growth Differentiation Factor-15 and Risk of CKD Progression. , 2017, Journal of the American Society of Nephrology : JASN.

[11]  Marc P. Bonaca,et al.  Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome: Observations From PROVE IT-TIMI 22 , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Akshay S. Desai,et al.  Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. , 2016, Journal of the American College of Cardiology.

[13]  P. Ponikowski,et al.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[14]  K. Unsicker,et al.  The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. , 2013, Cytokine & growth factor reviews.

[15]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.

[16]  Svati H Shah,et al.  Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. , 2015, JACC. Heart failure.

[17]  Sohail Q Khan,et al.  Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. , 2009, European heart journal.

[18]  F. Luft,et al.  Circulating and Placental Growth-Differentiation Factor 15 in Preeclampsia and in Pregnancy Complicated by Diabetes Mellitus , 2009, Hypertension.

[19]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[20]  M. Frenneaux,et al.  Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy , 2009, European heart journal.

[21]  A. Remppis,et al.  Reference change values and determinants of variability of NT-proANP and GDF15 in stable chronic heart failure , 2009, Basic Research in Cardiology.

[22]  R. Prager,et al.  Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes , 2016, Heart.

[23]  P. Ponikowski,et al.  Growth differentiation factor 15 (GDF‐15) in patients admitted for acute heart failure: results from the RELAX‐AHF study , 2015, European journal of heart failure.

[24]  W. Kraus,et al.  Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. , 2017, JACC. Heart failure.

[25]  W. Rottbauer,et al.  Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study. , 2016, Clinical chemistry.

[26]  H. White,et al.  State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. , 2017, Clinical chemistry.

[27]  A. Jaffe,et al.  Variability of biomarkers in patients with chronic heart failure and healthy controls , 2016, European journal of heart failure.

[28]  T. Cash-Mason,et al.  GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.